| Novel psychoactive substances of interest for psychiatry F Schifano, L Orsolini, G Duccio Papanti, JM Corkery World Psychiatry 14 (1), 15-26, 2015 | 313 | 2015 |
| Understanding the complex of suicide in depression: from research to clinics L Orsolini, R Latini, M Pompili, G Serafini, U Volpe, F Vellante, M Fornaro, ... Psychiatry investigation 17 (3), 207, 2020 | 271 | 2020 |
| Suicide during perinatal period: epidemiology, risk factors, and clinical correlates L Orsolini, A Valchera, R Vecchiotti, C Tomasetti, F Iasevoli, M Fornaro, ... Frontiers in psychiatry 7, 138, 2016 | 212 | 2016 |
| Mental health interventions during the COVID-19 pandemic: a conceptual framework by early career psychiatrists R Ransing, F Adiukwu, V Pereira-Sanchez, R Ramalho, L Orsolini, ... Asian journal of psychiatry 51, 102085, 2020 | 194 | 2020 |
| COVID-19 effect on mental health: patients and workforce V Pereira-Sanchez, F Adiukwu, S El Hayek, DG Bytyçi, JM Gonzalez-Diaz, ... The Lancet Psychiatry 7 (6), e29-e30, 2020 | 176 | 2020 |
| Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine D De Berardis, G Rapini, L Olivieri, D Di Nicola, C Tomasetti, A Valchera, ... Therapeutic advances in drug safety 9 (5), 237-256, 2018 | 173 | 2018 |
| Infectious disease outbreak related stigma and discrimination during the COVID-19 pandemic: Drivers, facilitators, manifestations, and outcomes across the world R Ransing, R Ramalho, R de Filippis, MI Ojeahere, R Karaliuniene, ... Brain, behavior, and immunity 89, 555, 2020 | 159 | 2020 |
| The prevalence and predictors of bipolar and borderline personality disorders comorbidity: systematic review and meta-analysis M Fornaro, L Orsolini, S Marini, D De Berardis, G Perna, A Valchera, ... Journal of affective disorders 195, 105-118, 2016 | 158 | 2016 |
| Eradicating suicide at its roots: preclinical bases and clinical evidence of the efficacy of ketamine in the treatment of suicidal behaviors D De Berardis, M Fornaro, A Valchera, M Cavuto, G Perna, M Di Nicola, ... International journal of molecular sciences 19 (10), 2888, 2018 | 157 | 2018 |
| Alexithymia and suicide risk in psychiatric disorders: a mini-review D De Berardis, M Fornaro, L Orsolini, A Valchera, A Carano, F Vellante, ... Frontiers in psychiatry 8, 148, 2017 | 145 | 2017 |
| Can COVID-19 related mental health issues be measured? R Ransing, R Ramalho, L Orsolini, F Adiukwu, JM Gonzalez-Diaz, ... Brain, behavior, and immunity 88, 32, 2020 | 132 | 2020 |
| Use of medicinal cannabis and synthetic cannabinoids in post-traumatic stress disorder (PTSD): a systematic review L Orsolini, S Chiappini, U Volpe, D De Berardis, R Latini, GD Papanti, ... Medicina 55 (9), 525, 2019 | 132 | 2019 |
| An update of safety of clinically used atypical antipsychotics L Orsolini, C Tomasetti, A Valchera, R Vecchiotti, I Matarazzo, F Vellante, ... Expert opinion on drug safety 15 (10), 1329-1347, 2016 | 131 | 2016 |
| Serotonin reuptake inhibitors and breastfeeding: a systematic review L Orsolini, C Bellantuono Human Psychopharmacology: Clinical and Experimental 30 (1), 4-20, 2015 | 122 | 2015 |
| Mind navigators of chemicals' experimenters? A web-based description of e-psychonauts L Orsolini, GD Papanti, G Francesconi, F Schifano Cyberpsychology, Behavior, and Social Networking 18 (5), 296-300, 2015 | 101 | 2015 |
| Targeting the noradrenergic system in posttraumatic stress disorder: a systematic review and meta-analysis of prazosin trials DD Berardis, S Marini, N Serroni, F Iasevoli, C Tomasetti, ... Current drug targets 16 (10), 1094-1106, 2015 | 100 | 2015 |
| Characteristics of deaths associated with kratom use JM Corkery, P Streete, H Claridge, C Goodair, D Papanti, L Orsolini, ... Journal of psychopharmacology 33 (9), 1102-1123, 2019 | 95 | 2019 |
| Profiling online recreational/prescription drugs' customers and overview of drug vending virtual marketplaces L Orsolini, G Francesconi, D Papanti, A Giorgetti, F Schifano Human Psychopharmacology: Clinical and Experimental 30 (4), 302-318, 2015 | 92 | 2015 |
| Protein-C reactive as biomarker predictor of schizophrenia phases of illness? A systematic review L Orsolini, F Sarchione, F Vellante, M Fornaro, I Matarazzo, G Martinotti, ... Current neuropharmacology 16 (5), 583-606, 2018 | 87 | 2018 |
| The FDA “black box” warning on antidepressant suicide risk in young adults: more harm than benefits? M Fornaro, A Anastasia, A Valchera, A Carano, L Orsolini, F Vellante, ... Frontiers in psychiatry 10, 294, 2019 | 84 | 2019 |
